Professor Philip Beart

Prof Philip Beart
Prof Philip Beart

BSc (Hons) (Adel) PhD (ANU) DSc (Melb)

Senior Principal Research Fellow
Brain Injury and Repair Group
Laboratory Head, Molecular Neuropharmacology Laboratory

Contact Details

Email:

philip.beart@florey.edu.au

Phone:

+61 (0)3 8344 1955

Fax:

+61 (0)3 9347 0446

Research Interests

Laboratory Techniques

Additional Information

Philip Beart is internationally renowned for his work on the neurochemical pharmacology and anatomy of amino acid, amine and peptide neurotransmitters. In particular he has made major contributions to our understanding of the key excitatory transmitter, L-glutamate, in terms of defining the organisation of its neurons in brain, and the pharmacology of glutamate receptors and transporters, and their involvement in excitotoxic brain injury. Long-term interests in structure activity relationships and drug development, and interactions with various international and Australian pharmaceutical companies (various patents).

Prof Beart has been a NHMRC Research Fellow since 1980 and currently holds an appointment at the professorial level. He has published over 200 peer-reviewed papers (over 4000 citations), of which 45 papers have been cited on 25-99 occasions and six papers have been cited over 100 times.

Prof Beart undertook postdoctoral training at Cambridge (UK) and Harvard (USA) Universities, and has been a visiting scientist in Cambridge (1983), London (1984 & 9), Bristol (1986), Copenhagen (1992), Montpellier (1999) and Paris (2004).

He is currently a Councillor of the International Society for Neurochemistry (2005-9), and was formerly Councillor of ANS (1989-1992) and ASCEPT (1989 & 1990, 1997 & 1998). Program Chair for 20th Congress of the International Society for Neurochemistry, Innsbruck, Austria (2005) and Convenor the 8th ISN Advanced School of Neurochemistry (Mexico) in 2007. Inaugural Board Member of Neurosciences Victorian Incorporated (2000-2).

Awards

Editorial Boards

Publications and Articles

Please see PubMed.

Excitatory amino acid projections to the nucleus accumbens septi in the rat. A retrograde transport study utilizing D[3H]aspartate and [3H]GABA. Neuroscience, 22, 425-439, 1987.

Regulation of σ-receptors: high and low affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-di(2-tolyl)guanidine.  Journal of Neurochemistry, 53, 779-788, 1989.

High affinity transport of L-[3H]-arginine in cultured neurons: characteristics and inhibition by nitric oxide synthase inhibitors.  Journal of Neurochemistry, 61, 364-367, 1993.

Transgenic mice expressing human Bc1-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.  Proc. Nat. Acad. Sci. (USA), 95, 5789-5794, 1998.

Micromolar L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurons.  Neuropharmacology, 37, 1419-1429, 1998.

Delayed treatment with AM-36, a novel neuroprotective agent, reduces delayed neuronal damage after endothelin-1 induced middle cerebral artery occlusion in conscious rats.  Stroke 30, 2704-2712, 1999.

[3H]-(2S,4R)-4-Methylglutamate: a novel ligand for the characterisation of glutamate transporters,  Journal of Neurochemistry, 77, 1218-1225, 2001.

BAY 36-7620 is a new non-competitive mGlu1 receptor antagonist and the first inverse agonist on mGlu1a,  Molecular Pharmacology, 59, 1-9, 2001.

Astrocyte mGlu2/3-mediated cAMP potentiation is calcium-sensitive: studies in murine neuronal and astrocyte cultures.  Neuropharmacology 43, 189-203, 2002.

Cholecystokinin regulates migration of gonadotrophin-releasing hormone-1 (GnRH-1) neurons in vivo and in vitro,  Journal of Neuroscience, 24: 4737-4748, 2004.

Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures.  Biochemical Pharmacology,69, 339-345, 2005.

NMDA-mediated neurotoxicity is potentiated by intravenous tissue-type, but not vampire bat-plasminogen activator, and is enhanced by fibrin.  Stroke 36, 1241-1246, 2005.

Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells.  Journal of Neurochemistry, 95:599-608, 2005.

Effects of lipopolysaccharide on glial phenotype and activity of glutamate transporters: evidence for delayed up-regulation and redistribution of GLT-1.  Neurochemistry International 48, 604-610, 2006.

Relative timing of redistribution of cytochrome c and Smac/DIABLO from mitochondria during apoptosis assessed by double immunocytochemistry on mammalian cells.  Experimental Cell Research 312, 1174-1184, 2006.

Hypoxic preconditioning produces differential expression of hypoxia-inducible factor-1α (HIF-1α) and its regulatory enzyme HIF prolyl hydroxylase 2 in neonatal rat brain.  Neuroscience Letters 404, 72-77, 2006.

Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein disulfide isomerase with superoxide dismutase 1.  Journal of Biological Chemistry 281, 30152-30165, 2006.

About